

# Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy

Makoto Kadokura<sup>1</sup>\*, Shinya Maekawa<sup>1\*</sup>\*, Ryota Sueki<sup>1</sup>, Miika Miura<sup>1</sup>, Kazuki Komase<sup>1</sup>, Hiroko Shindo<sup>1</sup>, Fumitake Amemiya<sup>1</sup>, Tomoyoshi Uetake<sup>1</sup>, Taisuke Inoue<sup>1</sup>, Minoru Sakamoto<sup>1</sup>, Mina Nakagawa<sup>2</sup>, Naoya Sakamoto<sup>2</sup>, Mamoru Watanabe<sup>2</sup>, Nobuyuki Enomoto<sup>1</sup>

**1** First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan, **2** Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Bunkyo, Tokyo, Japan

## Abstract

**Background and Aims:** Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and treatment outcome remains unclear.

**Methods:** The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct sequencing were investigated for correlation with the final outcome in a total of 60 patients.

**Results:** In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n = 16) were relapsers. Compared to sustained virological response (SVR) patients (n = 44), non-SVR patients were older and could not achieve prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted. Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid substitutions were associated with the final outcome in an incremental manner, depending upon the number of substitutions.

**Conclusions:** Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of the ISDR, were extracted as having significant correlation with the final outcome.

**Citation:** Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, et al. (2011) Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy. PLoS ONE 6(9): e24514. doi:10.1371/journal.pone.0024514

**Editor:** John E. Tavis, Saint Louis University, United States of America

**Received:** March 10, 2011; **Accepted:** August 12, 2011; **Published:** September 15, 2011

**Copyright:** © 2011 Kadokura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported in part by a grant-in-aid scientific research fund of the Ministry of Education, Science, Sports and Culture number 20390206 and in part by a grant-in-aid from the Ministry of Health, Labour, and Welfare of Japan (H19-kanen-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: maekawa@yamanashi.ac.jp

§ These authors contributed equally to this work.

## Introduction

Worldwide, 180 million people are estimated to be infected with hepatitis C virus (HCV), a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [1]. In HCV-infected patients with chronic hepatitis, treatment with interferon (IFN)-based therapy can result in viral clearance as well as biochemical and histological improvements [2]. In this IFN-based therapy, HCV genotype is the most significant factor affecting treatment responses [3,4].

In genotype 2b HCV infection, 80% of patients with high viral titers can achieve a sustained virological response (SVR) to the regimen of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks [5,6]. This response is high considering that much

lower percentages of patients infected with other genotypes can achieve SVR, especially with genotype 1 [1]. However, in other words, 20% of patients infected with genotype 2b HCV still cannot clear the virus and remain at risk of developing HCC. On the other hand, although various studies have been undertaken to clarify the factors contributing to the response to IFN-based therapy in genotype 1 infection, it remains poorly understood which patients with genotype 2b HCV infection will show unfavorable responses. Recently, the significance of IL28B single nucleotide polymorphisms (SNPs) in determining the response to PEG-IFN/RBV therapy was demonstrated in genotype 1 HCV infection [7,8]. However, the significance of IL28B SNPs was rather weak in genotype 2 HCV infection [9].

In terms of the association between HCV sequence variation and treatment responses, previous studies have reported that

**Table 1.** Baseline Characteristics of Studied Patients.

Characteristic	SVR (n = 44)	non-SVR (n = 16)	P value
Gender (Male/Female)	26/18	9/7	NS <sup>†</sup>
Age (yrs)	56 (22–72) <sup>*</sup>	59 (30–80)	0.04 <sup>†</sup>
BMI	23.5 (16.6–30.3)	24.7 (18.5–31.7)	NS <sup>‡</sup>
ALT (IU/l)	51 (19–380)	41 (17–390)	NS <sup>‡</sup>
GGTP (IU/l)	36 (11–133)	40 (17–292)	NS <sup>‡</sup>
T.Chol (mg/dl)	169 (119–225)	178 (145–217)	NS <sup>‡</sup>
WBC (/μl)	4600 (2620–7200)	5080 (3270–8600)	NS <sup>‡</sup>
Hb (g/dl)	14.2 (11.5–17.3)	14.6 (11.8–16.4)	NS <sup>‡</sup>
Platelet ( $\times 10^4/\text{mm}^3$ )	19 (7.1–31.8)	17.8 (8–36.7)	NS <sup>‡</sup>
Fibrosis score (0–2/ $\geq 3$ ) <sup>§</sup>	38/5	7/3	NS <sup>†</sup>
HCV RNA (KIU/ml)	2050 (100–16000)	1800 (140–6300)	NS <sup>‡</sup>
IFN dose ( $\geq 80\%/60\text{--}80\%$ )	36/8	13/3	NS <sup>†</sup>
Ribavirin dose ( $\geq 80\%/60\text{--}80\%$ )	32/12	10/6	NS <sup>†</sup>
RVR rate (%)	55.8	6.3	0.0008 <sup>†</sup>
EVR rate (%)	97.7	68.8	0.004 <sup>†</sup>
ETR rate (%)	100	87.5	NS <sup>†</sup>

§: SVR : n = 43, non-SVR : n = 10.

\*: median (range).

†: Fisher's exact probability test.

‡: Mann-Whitney's U test.

doi:10.1371/journal.pone.0024514.t001


amino acid variation in the NS5A-ISDR [10], NS5A-IRRDR [11], NS5B [12], PKR-eIF2 phosphorylation homology domain (PePHD) of E2 [13], and Core [14] correlate with the clinical outcome of IFN-based therapy, including PEG-IFN/RBV therapy for genotype 1b HCV infection. In the meantime, these viral sequence studies have been controversial regarding their true clinical importance, because the results of different studies were not always coincident [15,16,17]. On this background, recent studies trying to analyze the correlation of complete HCV open reading frame diversity, clinical characteristics, and the response to PEG-IFN/RBV therapy for genotype 1 HCV infection, in the most comprehensive approach yet attempted, have clarified that viral amino acid variation is associated with treatment responses, with consideration of racial background [18,19]. In genotype 2 infection, however, only a few studies have investigated the association of HCV sequence variation and treatment response [20,21] and the clinical significance has been yet established. We reported recently that variation of amino acid (aa) 110 in Core and amino acids (aa) 2258–2308 in NS5A were significantly associated with treatment outcome of the PEG-IFN/RBV therapy for genotype 2a HCV infection, through the analysis of the complete HCV ORFs in Japanese patients [22].

In this study, to assess comprehensively the influence of viral sequence variation on the response to the PEG-IFN/RBV therapy in genotype 2b HCV infection, we determined the complete pretreatment HCV ORFs from Japanese patients and investigated amino acid variation and its correlation with the response to combination therapy with PEG-IFN plus RBV.


## Methods

### Patients

A total of 77 adult Japanese patients infected with genotype 2b HCV, who received the combination therapy with PEG-IFN




**Figure 1. Phylogenetic analysis of the genotype-2b polyprotein sequences.** In order to perform the phylogenetic analysis, we first aligned all 60 HCV complete ORF amino acid sequences obtained from the patients along with reference sequences (2b.HC-J8.D10988, 2b.JP.MD2b9-2, and 2a.JP.JFH-1.AB047639), using the ClustalW program, and constructed the phylogenetic tree using the Neighbor-Joining method with MEGA version 4 software. Blue circles indicate SVR patients and red circles indicate non-SVR patients. doi:10.1371/journal.pone.0024514.g001



**Figure 2. Number of amino acid substitutions per sample in the sustained virological responders (SVR) and the non-sustained virological responders (non-SVR) group.** The numbers of variations, relative to a population consensus, that were unique to either SVR or non-SVR patients are shown for the complete open reading frame (ORF) (Fig. 1, left) and for each HCV protein (Fig. 1, right). doi:10.1371/journal.pone.0024514.g002

(PEGINTRON®, Schering-Plough, Tokyo, Japan) plus RBV (REBETOL®, Schering-Plough) between 2005 and 2009 at University of Yamanashi, Tokyo Medical and Dental University,

and related institutions were first included in the study. They all fulfilled following criteria: (1) negative for hepatitis B surface antigen, (2) high viral load ( $\geq 100$  KIU/ml), (3) absence of



**Figure 3. Different amino acid usage at each viral amino acid position between the sustained virological responders (SVR) and the non-sustained virological responders (non-SVR) patients.** (a) Different amino acid usage at each viral amino acid position between the SVR and the non-SVR patients was analyzed by Fisher's exact probability test. The longitudinal axis shows the  $-\log P$  value. (b) Sequence alignment in the Core region is demonstrated. Dashes indicate amino acids identical to the consensus sequence and substituted amino acids are shown by standard single letter codes. doi:10.1371/journal.pone.0024514.g003

**Table 2.** Variation at each Amino Acid Position and SVR rate.

	E2 aa 404 non T	E2 aa 530 non T	NS5A aa 2359 N	NS5B aa 2631 non P
SVR rate	86.1% (31*/36**, p=0.008)	87.9% (29/33, p=0.008)	82% (41/50, p=0.002)	94.7% (18/19, p=0.012)

\*SVR number in patients fulfilling the criteria.

\*\*Number of patients fulfilling the criteria.

doi:10.1371/journal.pone.0024514.t002


hepatocellular carcinoma, (4) no other form of hepatitis, such as primary biliary cirrhosis, autoimmune liver disease, or alcoholic liver disease, (5) free of co-infection with human immunodeficiency virus. To clearly disclose the non-SVR viral characteristics, we have considered only those patients who achieved total drug administration of 60% or more for both PEG-IFN and RBV, with the completion of the standard treatment duration. Moreover, although we excluded patients with extended therapy to make the studied population uniform, we have included non-SVR patients with extended therapy to clarify the specific characteristics of non-SVR patients, a minor population group. As a result, 17 patients were excluded for the following reasons: 1 patient received insufficient dose, 4 patients were discontinued from the therapy within 12 weeks, and 12 SVR patients received extended therapy. Finally, 60 patients were considered as eligible for the study. During the combination therapy, blood samples were obtained at least once every month before, during and after treatment and were analyzed for blood count, ALT and HCV RNA levels. Liver biopsy specimens were obtained from most of the patients. All patients gave written informed consent to the study. The study was approved by the ethics committees of University of Yamanashi,

Tokyo Medical and Dental University, and related institutions. The therapy was performed according to the standard treatment protocol of PEG-IFN/RBV therapy for Japanese patients established by a hepatitis study group of the Ministry of Health, Labour, and Welfare, Japan (PEG-IFN $\alpha$ -2b 1.5  $\mu$ g/kg body weight, once weekly subcutaneously, and RBV 600–800 mg daily per os for 24 weeks).

#### Complete HCV-ORF Sequence Determination by Direct Sequencing from Pretreatment Sera

HCV RNA was extracted from pretreatment serum samples by the AGPC method using Isogen (Wako, Osaka, Japan) according to the following protocol. Briefly, 150  $\mu$ l of serum were mixed with 700  $\mu$ l of Isogen, and an aqueous phase was extracted with 150  $\mu$ l of chloroform. RNA was precipitated with 600  $\mu$ l of isopropanol and with 2  $\mu$ l of Glyco Blue (Ambion, Tokyo, Japan) as a carrier. The purified RNA was washed once with ethanol and finally dissolved in 15  $\mu$ l of distilled water and stored at  $-70^{\circ}\text{C}$  until use.

Complementary DNA was synthesized according to the following protocol. 30  $\mu$ l of the reverse transcription mixture were adjusted to contain 3  $\mu$ l of the RNA solution, 300 U of Superscript



**Figure 4. Sliding window analysis.** (a) Comparison of amino acid variation between the SVR and non-SVR patients across HCV “regions” using sliding window analysis was performed. Viral regions affecting treatment outcome are shown as red areas. There are six hot areas: amino acid 400–408 and 723–770 in the E2 region, amino acid 879–893 in the NS2 region and, amino acid 2045–2051, 2224–2242 and 2379–2405 in the NS5A region. (b) Sequence alignment in the nonstructural (NS)5A around amino acids 2213 to 2274 is demonstrated. Dashes indicate amino acids identical to the consensus sequence and substituted amino acids are shown by standard single letter codes.

doi:10.1371/journal.pone.0024514.g004

**Table 3.** Number of Amino Acid Substitutions in each Region and SVR rate.

	E2 aa 400–408 mutation $\geq 4$	E2 aa 723–770 mutation $\geq 2$	NS2 aa 879–893 mutation $\geq 2$	NS5A aa 2045–2051 absense of mutation	NS5A ISDR (aa 2213–2248) mutation $\geq 1$	NS5A aa 2224–2242 mutation $\geq 1$	NS5A aa 2379–2405 mutation $\geq 2$
SVR rate	86.5% (32*/37**) p=0.006	100% (18/18) p=0.001	94.7% (18/19) p=0.01	89.7% (35/39) p=0.0002	86.1% (31/36) p=0.008	90.9% (30/33) p=0.001	90.9% (20/22) p=0.03

\*SVR number in patients fulfilling the criteria.

\*\*Number of patients fulfilling the criteria.

doi:10.1371/journal.pone.0024514.t003

II (Invitrogen, Tokyo, Japan) with an accompanied buffer according to the manufacturer's instructions, 60 units of RNase inhibitor (Promega Corp., Madison, WI), and 300 pg of random primers (Invitrogen). The mixture was incubated at 37°C for 30 min. The HCV genome was amplified with 24 partially overlapping primer (Table S6) sets, designed specifically for this study, to perform two-step nested PCR. As previously reported, a M13 forward primer (5'-TGTA AACGACGGCCAGT-3') and a M13 reverse primer (5'-CAGGAAACAGCTATGACC-3') were attached to the 5' termini of the sense and antisense second-round PCR primers, respectively, to facilitate direct sequencing. All samples were initially denatured at 95°C for 7 min., followed by 40 cycles with denaturation at 95°C for 15 seconds, annealing at 55°C for 15 seconds, and extension at 72°C for 45 seconds with BD Advantage™ 2 PCR Enzyme System (BD Biosciences Clontech, CA, USA). PCR amplicons were sequenced directly by Big Dye Terminator Version 3.1 (ABI, Tokyo, Japan) with universal M13 forward/M13 reverse primers using an ABI prism 3130 sequencer (ABI). The sequence files generated were assembled using Vector NTI software (Invitrogen) and base-calling errors were corrected following visual inspection of the chromatogram. When several peaks were observed at the same nucleotide position in the chromatogram, the highest chromatogram peak was read as the dominant nucleotide. In sequence analysis, multiple sequence alignment was performed with ClustalW, and the mean genetic distance was calculated using the p-distance algorithm in the MEGA version 4 DNA software. As a result, 60 genotype-2b HCV full open reading frame sequences were determined. In Table S1, obtained GenBank accession numbers for these sequences determined in this study are listed.

**Table 4.** Multivariate Logistic Regression Analysis.

Factor	odds (95% CI)	p value
Age	0.94 (0.85–1.04)	0.20
E2 aa 530 non T	4.33 (0.48–39.3)	0.19
NS5A aa 2359 N	3.22 (0.18–57.7)	0.43
NS5B 2631 non P	5.14 (0.29–91.2)	0.26
NS2 aa 879–893 mutations $\geq 2$	9.77 (0.52–182)	0.13
NS5A aa 2045–2051 no mutations	4.46 (0.39–50.6)	0.23
NS5A aa 2224–2242 mutations $\geq 1$	11.0 (1.13–107)	0.04
NS5A aa 2379–2405 mutations $\geq 1$	7.03 (0.62–79.8)	0.12

To evaluate the optimal threshold of amino acid variations for SVR prediction in each viral region extracted, a receiver operating characteristic curve was constructed and the most optimal cut off value was determined for each region.

doi:10.1371/journal.pone.0024514.t004

### Sliding Window Analysis

A sliding window analysis was introduced to search through HCV amino acid “regions”, rather than single amino acid positions, related to the final outcome of PEG-IFN/RBV therapy. Briefly, the total number of amino acid substitutions compared to the consensus sequence within a given amino acid length were counted at each amino acid position in each HCV sequence. The consensus sequence was generated from these 60 patients. Then the relation of substitution numbers and the final outcome was compared statistically between the SVR and non-SVR groups by Mann-Whitney's U test for each amino acid position. In this study, we changed the window length from 1 to 50 to search for those HCV regions. To visualize the result, significantly lower p-values were colored in red and non-significant p-values were colored in green using Microsoft Excel software to generate a “heat map” appearance. In the present study, p-value of 1/300 or lower was colored in the maximum red.


### Statistical Analysis

Statistical differences in the parameters, including all available patients' demographic, biochemical, hematological, and virological data such as sequence variation factors, were determined between the various groups by Mann-Whitney's U test for numerical variables and Fisher's exact probability test for categorical variables. To evaluate the optimal threshold of variations for SVR prediction, a receiver operating characteristic curve was constructed and the area under the curve as well as the sensitivity and specificity were calculated. Variables that achieved statistical significance ( $p < 0.05$ ) in univariate analysis were entered into multiple logistic regression analysis to identify significant independent factors. We also calculated the odds ratios and 95% confidence intervals. All p values of  $< 0.05$  by the two-tailed test were considered significant.

### Results

#### Characteristics of the patients studied

The SVR rate of the patients analyzed was 75.9% (44/58) with the standard therapy (two non-SVR patients received extended therapy). The baseline characteristics of the patients classified according to achievement of SVR are shown in Table 1. Rapid virological response (RVR; undetectable serum HCV RNA within 4 weeks) and early virological response (EVR; undetectable serum HCV RNA within 12 weeks) rates were significantly higher in SVR patients ( $p = 0.0008$  and  $0.004$ ). In addition, patients with non-SVR were older ( $p = 0.04$ ). Pretreatment HCV RNA titer, which is known to affect the treatment outcome in genotype 1 and 2a HCV infection, did not differ significantly between two groups. Achievement of RVR reached 42.4% when all patients were included, and this rate was high compared to achievement of RVR in patients with genotype 1b infection (~10%) observed in



**Figure 5. Correlation between pretreatment HCV RNA levels and the number of substitutions in the NS5A region aa 2224 to 2242.** Spearman's correlation coefficient by rank test is demonstrated. doi:10.1371/journal.pone.0024514.g005

University of Yamanashi (data not shown). The early virological response (EVR) rate was equally high in the SVR (97.7%) and non-SVR (68.8%) groups. Interestingly, most of the non-SVR patients (14/16, 87.5%) in genotype-2b HCV infection showed end-of-treatment response (ETR; undetectable serum HCV RNA at the end of therapy), demonstrating that the main cause of non-SVR was relapse (reappearance of hepatitis C viremia during the follow-up period after stopping therapy) in patients with an ETR,

n = 14), and not null response (detectable serum HCV RNA at the end of therapy, n = 2).

#### Phylogenetic analysis of SVR and non-SVR patients using the complete HCV amino acid sequence

To determine the viral sequence characteristics in the SVR and non-SVR groups, we first aligned all 60 HCV complete ORF amino acid sequences obtained from the patients' pretreatment sera along

**Table 5. Baseline Characteristics of patients with NS5A aa 2224–2242 variations none or 1 ≤.**

Characteristic	Variation 1 ≤ (n = 33)	No variation (n = 27)	P value
Gender (Male/Female)	17/16	18/9	NS <sup>†</sup>
Age (yrs)	57 (29–72) <sup>*</sup>	57 (22–80)	NS <sup>‡</sup>
ALT (IU/l)	72 (19–380)	47 (17–390)	NS <sup>‡</sup>
Platelet ( $\times 10^4/\text{mm}^3$ )	19.3 (7.1–31.8)	17.5 (10.4–36.7)	NS <sup>‡</sup>
Fibrosis score (0–2/≥3) <sup>§</sup>	26/5	19/3	NS <sup>†</sup>
HCV RNA (KIU/ml)	1600 (100–16000)	2450 (140–13000)	NS <sup>‡</sup>
IFN dose (≥80%/60–80%)	26/7	23/4	NS <sup>†</sup>
Ribavirin dose (≥80%/60–80%)	24/9	19/8	NS <sup>†</sup>
RVR rate (%)	53.1	29.6	NS <sup>†</sup>
EVR rate (%)	96.9	81.5	NS <sup>†</sup>
SVR rate (%)	90.9	51.9	0.001 <sup>†</sup>
Relapse rate (%)	40.7	9.1	0.006 <sup>†</sup>

<sup>§</sup>: 1 ≤ : n = 31, 0 : n = 22.

<sup>\*</sup>: median (range).

<sup>†</sup>: Fisher's exact probability test.

<sup>‡</sup>: Mann-Whitney's U test.

doi:10.1371/journal.pone.0024514.t005

with reference sequences (2b.HC-J8.D10988, 2.JP.MD2b9-2, and 2a.JP.JFH-1.AB047639 obtained from the Los Alamos HCV Database as representative sequences for genotype 2b and genotype 2a HCV) and constructed a phylogenetic tree (Fig. 1). As demonstrated in the tree, no evident clustering was apparent according to the difference of responses.

### Comparison of amino acid variation between the SVR and non-SVR in the complete HCV polyprotein and each HCV protein

Next, we compared amino acid variations that were unique, relative to a population consensus, to either the SVR or non-SVR patients for the complete HCV polyprotein and each HCV protein. The number of amino acid variations in the sequences from the SVR patients was significantly higher than in those from the non-SVR patients, when the entire HCV polyprotein was analyzed (Fig. 2, left). These differences were especially significant in E1, p7 and NS5A (Fig. 2, right). This result demonstrated that HCV sequences from patients with SVR comprised a heterogeneous population, while HCV sequences from patients with non-SVR comprised a rather homogeneous population, indicating the existence of unique non-responsive HCV sequences in those regions in E1, p7, and NS5A.

### Comparison of HCV sequence variation between the SVR and non-SVR patients at each amino acid position

Each amino acid position in the HCV ORF was compared to detect any differences between the SVR and non-SVR patients. In Fig. 3a, differences in amino acid residues at each position are shown as dots demonstrating  $-\log P$  values. As shown in Table 2, four points were extracted: amino acid (aa) 404 in the E2 region ( $p = 0.008$ ), aa 530 in the E2 region ( $p = 0.008$ ), aa 2359 in the NS5A region ( $p = 0.002$ ) and aa 2631 in the NS5B region ( $p = 0.012$ ). Among them, the residue at aa 2359 in the NS5A region differed most frequently between the SVR and non-SVR patients. Amino acids 4 and 110 in the Core region, residues that have been reported to vary according to the virological responses in genotype 2a infection [22,23], did not differ significantly in this genotype 2b HCV study. Meanwhile, amino acids 70 and 91, which have been reported to vary according to virological response to PEG-IFN/RBV therapy in genotype 1b infection, were conserved irrespective of the outcome (Fig. 3b).

### Comparison of amino acid variation between the SVR and non-SVR patients across HCV "regions" using sliding window analysis

Fig. 4a and Table 3 shows the result of sliding window analysis. This approach was used to detect differing HCV amino acid "regions", rather than single amino acid positions, between the SVR and the non-SVR patients. According to the result, six regions were associated with the final outcome ( $p$ -values less than 1/20): aa 400–408 in the E2 region ( $p = 0.006$ ), aa 723–770 in the E2 and the N-terminus of p7 region ( $p = 0.001$ ), aa 879–893 in the NS2 region ( $p = 0.01$ ), aa 2045–2051 in the NS5A region ( $p = 0.0002$ ), aa 2224–2242 in the NS5A region ( $p = 0.001$ ) and aa 2379–2405 in the NS5A region ( $p = 0.03$ ). Interestingly, aa 2224–2242 in the NS5A was located in the interferon sensitivity determining region (ISDR). Fig. 4b shows the aligned sequences of amino acids around 2213–2274 of HCV NS5A. Among these 6 regions, aa 723–770, aa 879–893, aa 2224–2242, and aa 2379–2405 were correlated with the final outcome in an incremental manner according to the number of substitutions in those regions (Table S2, S3, S4, S5). The number of substitutions in the ISDR

was also correlated to the final outcome in an incremental step-up manner (data not shown).

### Multivariate analysis to detect independent predictive factors contributing to the SVR

Next, multivariate analysis was undertaken to identify pretreatment variables correlated with the final outcome. To evaluate the optimal threshold of amino acid variations for SVR prediction in each viral region extracted, a receiver operating characteristic curve was constructed and the most optimal cut off value was determined for each region. E2 aa 404–408 was excluded from the analysis because we considered that the region was unlikely to be truly associated to the outcome as it is located in the hypervariable region, the region of the highest mutation rate in the HCV genome as a result of host's immune attack. E2 aa 723–770 was excluded from the analysis because all the patients above the cut-off value in the region achieved SVR and an odds calculation was not possible. The ISDR was also excluded because NS5A aa 2224–2242 was completely contained in the ISDR. In addition, variables of EVR and RVR were excluded because they were post treatment variables. The multivariate analysis revealed that only NS5A aa 2224–2242 (odds ratio 11.0,  $p = 0.039$ ) was finally identified as the independent variable predicting the final outcome (Table 4).

### Biological relevance of variation in NS5A in this study group

Because NS5A aa 2224–2242 is located within the ISDR, for which the amino acid substitution numbers have been reported to be correlated with the HCV RNA titer in genotype 1 and 2a HCV infection [13], we analyzed the relationship between amino acid variations in that region and pretreatment HCV RNA titers. Contrary to our expectation, no evident relationship was found between variations in the NS5A region aa 2224–2242 and HCV RNA titer (Fig. 5). On the other hand, as shown in Table 5, although the initial viral responses (RVR or EVR) did not show evident association with the amino acid variations in the region, treatment relapse was significantly correlated with the amino acid variations in the region. In addition to NS5A aa 2224–2242, there was no evident relationship between HCV RNA level and variations in the other regions found in this study (data not shown).

### Discussion

In this study, we showed that genotype 2b HCV sequences from Japanese patients who achieved SVR were more diverse than the sequences from patients with non-SVR. The result that SVR patients were more diverse in their HCV sequences than non-SVR patients is in accordance with previous studies of genotype 1 HCV infection, although the diverse viral genes varied according to genotype [18,19]. We found that these diversities were primarily found in E1, p7 and NS5A.

In systemic searching for single amino acid positions or consecutive amino acid regions in the HCV ORF associated with the treatment outcome, several regions were extracted in E2, p7, NS2, NS5A and NS5B. Among those identified regions, E2 aa 723–770, NS2 aa 879–893, NS5A aa 2224–2242, and NS5A aa 2379–2405 were correlated with the final outcome in an incremental manner according to the number of amino acid substitutions. Specifically, the sequences of those regions in non-SVR patients were almost homogeneous, while the sequences of the region in SVR patients were significantly diverse and multiple amino acid substitutions were found compared to the consensus sequence. Interestingly, among those regions, aa 2224–2242 was completely included in the ISDR, in which the number of amino acid substitutions is known to show significant correlation with

the treatment response to IFN-based therapy in genotype 1b, and also in genotype 2 [21,24].

In recent studies of genotype 1b infection, amino acid variation of residues 70 and 91 in the Core were reported to be associated with the treatment response to IFN-based therapy. The correlation of amino acid variation in the Core (residues 4 and 110) with the response to PEG-IFN/RBV therapy was also identified in genotype 2a infection [22,23]. In genotype 2b infection, however, we could not find such associations between amino acid variation in the core region and the response to PEG-IFN/RBV therapy (Fig. 3b). Amino acid residues of aa 70 and 91 were conserved irrespective of differences in the PEG-IFN/RBV responses. On the other hand, although amino acid variations were also sometimes found at residues 4 and 110 in genotype 2b HCV, their frequency was low, and no evident association between the variation and the treatment response was found. Although the reason of the lack of association between the Core and the PEG-IFN/RBV treatment response in genotype-2b HCV infection is unknown, it suggests that a different mechanism affecting the treatment response might exist, depending on genotype-specific viral features.

In genotype 1 HCV, variations within the PKR-binding region of NS5A, including those within the ISDR, were reported to disrupt the NS5A-PKR interaction, possibly rendering HCV sensitive to the antiviral effects of interferon [25]. Clinically, the number of substitutions within the ISDR has been reported to correlate with the serum HCV RNA level in genotype 1 and 2a infections [13]. In addition, a recent study reported that mutations in the ISDR also show the correlation with the relapse in the PEG-IFN/RBV therapy in genotype 1b infection [26]. Because NS5A aa2224–2242, part of ISDR, was extracted as one of those regions related to the treatment response in genotype 2b infection, we undertook further analysis to investigate the correlation between amino acid variation numbers and serum HCV RNA level. Though the reason is unknown, we could not find evidence of a relationship between variation in the NS5A aa 2224–2242 and HCV RNA titer in genotype 2b infection, unlike genotypes 1 and 2a. Of note, a high SVR rate in genotype 1 and genotype 2a infection is known to be closely correlated with a low HCV RNA level and multiple substitutions in ISDR. However, in genotype 2b infection in our study, there was no significant difference in the HCV RNA level between SVR and non-SVR patients, as shown in Table 1. Previously, the role of the ISDR in the contribution to SVR in genotype 1 and 2a has been discussed in detail in the context of serum HCV RNA level, and multiple substitutions in the ISDR are related to a low HCV RNA level and high SVR rate. However, it is not known which of these two factors is directly associated with viral clearance. Consideration of this three-sided relationship of ISDR, HCV RNA level and SVR rate in genotype-2b infection leads to the suggestion that amino acid variation in ISDR to be more direct contributor for SVR.

In spite of these findings, there were still limitations in our study. First, because genotype 2b infection only accounts for 10% of all HCV infection in Japan, the number of studied patients was rather small, especially non-SVR patients. In addition, because genotype 2b HCV contains as many as 3033 amino acids, it is possible that incorrect amino acids or regions were judged as significant in the complete HCV ORF comparison study as a result of type I errors.

## References

- Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 49: 1335–1374.
- Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, et al. (1989) Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med* 321: 1506–1510.
- Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, et al. (1998) Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. *Gut* 42: 570–575.
- Simmonds P (1997) Clinical relevance of hepatitis C virus genotypes. *Gut* 40: 291–293.

Therefore, if more patients were available for the analysis, the statistical power detecting the meaningful differences would be greater. Secondly, we could not include the IL28B SNP analysis in this study. If we could have combined the information of IL28B SNPs with the full HCV ORF information, a more comprehensive analysis would have been achieved.

In conclusion, we have shown that viral sequences were more diverse in SVR patients infected with genotype 2b HCV. Through systematic comparison between SVR and non-SVR patients, we have also shown that several localized regions were extracted as hot spots whose amino acid substitutions were closely related to the final outcome by affecting the relapse rate in the PEG-IFN/RBV therapy.

## Supporting Information

**Table S1 GenBank Accession Numbers.** Obtained GenBank accession numbers for 60 genotype-2b HCV full open reading frame sequences are listed. (DOC)

**Table S2 Substitutions in NS5A aa 2224–2242 Amino Acid Regions and SVR rate.** SVR rate increased with the number of substitutions in this region. (DOC)

**Table S3 Substitutions in NS5A aa 2379–2405 Amino Acid Regions and SVR rate.** SVR rate increased with the number of substitutions in this region. (DOC)

**Table S4 Substitutions in NS2 aa 879–893 Amino Acid Regions and SVR rate.** SVR rate increased with the number of substitutions in this region. (DOC)

**Table S5 Substitutions in E2 aa 723–770 Amino Acid Regions and SVR rate.** SVR rate increased with the number of substitutions in this region. (DOC)

**Table S6 PCR Primer List.** Primers designed to perform two-step nested PCR for this study are listed. Dominant genotype-2b HCV full open reading frame sequences was determined by the 24 partially overlapping amplicons amplified by these primers. (XLS)

## Acknowledgments

We are grateful to Yamanashi Pegintron Ribavirin Study Group and Ochanomizu Liver Conference Group for their cooperation and advice. Especially, we thank Asuka Kanayama and Takako Ohmori for their technical assistance, and Takatoshi Kitamura and Shunichi Okada for their cooperation and advice.

## Author Contributions

Conceived and designed the experiments: MK SM NE. Performed the experiments: MK. Analyzed the data: MK SM NE. Contributed reagents/materials/analysis tools: RS MM HS KK. Wrote the paper: MK SM NE. Critical revision of the manuscript for important intellectual content: FA TU TI MS MN NS MW.



5. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140: 346–355.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 358: 958–965.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461: 399–401.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41: 1105–1109.
9. Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, et al. (2010) Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study. *Gastroenterology*.
10. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 334: 77–81.
11. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. *Hepatology* 48: 38–47.
12. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, et al. (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. *J Gastroenterol Hepatol* 20: 1401–1409.
13. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, et al. (2000) Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. *Hepatology* 32: 1138–1144.
14. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, et al. (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48: 372–380.
15. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, et al. (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. *J Gen Virol* 79(Pt 6): 1373–1381.
16. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL, Jr., Gretch DR (1997) Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. *J Med Virol* 53: 118–126.
17. Zeuzem S, Lee JH, Roth WK (1997) Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. *Hepatology* 25: 740–744.
18. Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, et al. (2010) Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. *PLoS One* 5: e9032.
19. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, et al. (2007) Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J Virol* 81: 8211–8224.
20. Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, et al. (2002) Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. *Am J Gastroenterol* 97: 988–998.
21. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, et al. (1999) Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. *Hepatology* 30: 1045–1053.
22. Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, et al. (2011) Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. *Hepatol Int*. In Press.
23. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, et al. (2009) Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy. *Intervirology* 52: 301–309.
24. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, et al. (2009) Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. *J Med Virol* 81: 459–466.
25. Gale M, Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, et al. (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. *Mol Cell Biol* 18: 5208–5218.
26. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2010) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol*.

# Sequences in the Interferon Sensitivity-Determining Region and Core Region of Hepatitis C Virus Impact Pretreatment Prediction of Response to PEG-Interferon Plus Ribavirin: Data Mining Analysis

Masayuki Kurosaki,<sup>1</sup> Naoya Sakamoto,<sup>2</sup> Manabu Iwasaki,<sup>3</sup> Minoru Sakamoto,<sup>4</sup> Yoshiyuki Suzuki,<sup>5</sup> Naoki Hiramatsu,<sup>6</sup> Fuminaka Sugauchi,<sup>7</sup> Akihiro Tamori,<sup>8</sup> Mina Nakagawa,<sup>2</sup> and Namiki Izumi, MD<sup>1\*</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

<sup>2</sup>Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

<sup>3</sup>Department of Computer and Information Science, Seikei University, Tokyo, Japan

<sup>4</sup>First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan

<sup>5</sup>Department of Hepatology, Toranomon Hospital, Tokyo, Japan

<sup>6</sup>Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan

<sup>7</sup>Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan

<sup>8</sup>Department of Hepatology, Osaka City University Medical School, Osaka, Japan

The aim of the present study was to clarify the significance of viral factors for pretreatment prediction of sustained virological response to pegylated-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C using data mining analysis. Substitutions in the IFN sensitivity-determining region (ISDR) and at position 70 of the HCV core region (Core70) were determined in 505 patients with genotype 1b chronic hepatitis C treated with PEG-IFN plus RBV. Data mining analysis was used to build a predictive model of sustained virological response in patients selected randomly ( $n = 304$ ). The reproducibility of the model was validated in the remaining 201 patients. Substitutions in ISDR (odds ratio = 9.92,  $P < 0.0001$ ) and Core70 (odds ratio = 1.92,  $P = 0.01$ ) predicted sustained virological response independent of other covariates. The decision-tree model revealed that the rate of sustained virological response was highest (83%) in patients with two or more substitutions in ISDR. The overall rate of sustained virological response was 44% in patients with a low number of substitutions in ISDR (0–1) but was 83% in selected subgroups of younger patients (<60 years), wild-type sequence at Core70, and higher level of low-density lipoprotein cholesterol (LDL-C) ( $\geq 120$  mg/dl). Reproducibility of the model was validated ( $r^2 = 0.94$ ,  $P < 0.001$ ). In conclusion, substitutions in ISDR and Core70 of

HCV are significant predictors of response to PEG-IFN plus RBV therapy. A decision-tree model that includes these viral factors as predictors could identify patients with a high probability of sustained virological response. *J. Med. Virol.* 83:445–452, 2011.

© 2011 Wiley-Liss, Inc.

**KEY WORDS:** data mining; decision-tree model; ISDR; core region; PEG-interferon

## INTRODUCTION

The combination of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) is currently the most effective therapy for chronic hepatitis C, but the rate of sustained virological response after 48 weeks of therapy is about 50% in patients with HCV genotype 1b and a high HCV

Grant sponsor: Ministry of Health, Labor and Welfare, Japan. The authors report no conflicts of interest.

\*Correspondence to: Namiki Izumi, MD, Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan. E-mail: nizumi@musashino.jrc.or.jp

Accepted 26 October 2010

DOI 10.1002/jmv.22005

Published online in Wiley Online Library (wileyonlinelibrary.com).

RNA titer [Manns et al., 2001; Fried et al., 2002]. The most reliable means to predict sustained virological response is to monitor the viral response during the early weeks of treatment. The early virological response, defined as undetectable HCV RNA at week 12, is associated with a high rate of sustained virological response [Davis et al., 2003; Lee and Ferenci, 2008]. The rapid virological response, defined as undetectable HCV RNA at week 4 of therapy, is even more predictive of sustained virological response than the early virological response [Jensen et al., 2006; Yu et al., 2008; Izumi et al., 2010]. However, there is no established means that predicts the virological response before commencing treatment. Recent reports have revealed that single nucleotide polymorphisms located near the *IL28B* gene show a strong association with the response to PEG-IFN plus RBV therapy [Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009; Kurosaki et al., 2010c]. These findings indicate that the host factor is an important determinant of the treatment response. On the other hand, the present study's authors have reported that a stretch of 40 amino acids in the NS5A region of HCV, designated as the interferon sensitivity-determining region (ISDR), has a close association with the virological response to interferon mono-therapy [Enomoto et al., 1995, 1996; Kurosaki et al., 1997]. More recently, amino acid substitutions at positions 70 and 91 of the core region have been reported to be associated with response to PEG-IFN plus RBV combination therapy [Akuta et al., 2005, 2007a]. The impact of these HCV substitutions on treatment response is yet to be validated.

Decision-tree analysis is a core component of data mining analysis that can be used to build predictive models [Breiman et al., 1980]. This method has been used to define prognostic factors in various diseases such as prostate cancer [Garzotto et al., 2005], diabetes [Miyaki et al., 2002], melanoma [Averbook et al., 2002; Leiter et al., 2004], colorectal carcinoma [Zlobec et al., 2005; Valera et al., 2007], and liver failure [Baquerizo et al., 2003]. The major advantage of decision-tree analysis over logistic regression analysis is that the results of analysis are easy to understand. The simple allocation of patients into subgroups by following the flowchart form could define the predicted possibility of outcome [LeBlanc and Crowley, 1995].

Decision-tree analysis was used for the prediction of early virological response (undetectable HCV RNA within 12 weeks of therapy) to PEG-IFN and RBV combination therapy in chronic hepatitis C [Kurosaki et al., 2010a], and more recently for the pretreatment prediction of sustained virological response [Kurosaki et al., 2010b]. In the latter model, simple and noninvasive standard tests were used as parameters; specialized tests such as viral mutations and host genetics, or invasive tests such as liver histology, were not included because the aim of that model was for use in general medical practice, especially in some countries or areas where resources are limited. Thus, the impact of viral mutations or liver histology was not considered in that model.

The present study examined whether including viral substitutions in ISDR and the core region of HCV in the decision-tree model could improve its predictive accuracy over the previous model to identify chronic hepatitis C patients who are likely to respond to PEG-IFN plus RBV therapy.

## MATERIALS AND METHODS

### Patients

This multicenter retrospective cohort study included 505 chronic hepatitis C patients who were treated with PEG-IFN alpha-2b and RBV at Musashino Red Cross Hospital, Toranomon Hospital, Tokyo Medical and Dental University, Osaka University, Nagoya City University Graduate School of Medical Sciences, Yamanashi University, Osaka City University, and their related hospitals. The inclusion criteria were: (1) genotype 1b, (2) HCV RNA titer higher than 100 kIU/ml by quantitative PCR (Cobas Amplicor HCV Monitor v 2.0, Roche Diagnostic Systems, Pleasanton, CA), (3) no co-infection with hepatitis B virus or human immunodeficiency virus, (4) no other causes of liver disease, (5) patients having undergone liver biopsy prior to IFN treatment, (6) number of substitutions in ISDR having been determined, (7) substitutions in the amino acid positions 70 and 91 of the core region having been determined, and (8) completion of at least 12 weeks of therapy. Patients were treated with PEG-IFN alpha-2b (1.5 µg/kg) weekly plus RBV. The daily dose of RBV was adjusted by weight: 600 mg for <60 kg, 800 mg for 60–80 kg, and 1,000 mg for >80 kg. For the analysis, patients were assigned randomly to either the model building (304 patients) or validation (201 patients) groups. There were no significant differences in the clinical backgrounds between these two groups (Table I). Informed consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review committees of all concerned hospitals.

### Laboratory Tests

Hematological tests, blood chemistry, and HCV RNA titer were analyzed before therapy and at least once every month during therapy. Sequences of ISDR and the core region of HCV were determined by direct sequencing after amplification by reverse transcription and polymerase chain reaction as reported previously. At position 70 of the core region (Core70), arginine was defined as the wild type, and glutamine or histidine was defined as the mutant type. At position 91 of the core region, leucine was defined as the wild type and methionine was defined as the mutant type, as described previously [Akuta et al., 2005]. Fibrosis and activity were scored according to the METAVIR scoring system [Bedossa and Poynard, 1996]. Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis), and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of

TABLE I. Comparison of Pretreatment Factors Between Model Building and Validation Patients

	Model (n = 304)	Validation (n = 201)	P-value
Age (years)	55.6 (9.4)	56.0 (12.2)	0.80
Male (%)	53 (%)	55 (%)	0.13
Body mass index (kg/m <sup>2</sup> )	23.1 (3.1)	23.1 (4.0)	0.99
Albumin (g/dl)	4.0 (0.3)	4.0 (0.3)	0.47
Creatinine (mg/dl)	0.72 (0.15)	0.72 (0.14)	0.62
AST (IU/L)	63.3 (45.6)	58.9 (46.4)	0.91
ALT (IU/L)	78.7 (58.6)	74.5 (67.5)	0.68
GGT (IU/L)	53.2 (49.1)	57.4 (63.5)	0.43
Total cholesterol (mg/dl)	170.9 (32.6)	169.4 (34.1)	0.33
Triglyceride (mg/dl)	107.0 (44.7)	105.7 (48.0)	0.90
LDL-C (mg/dl)	95.5 (28.0)	96.4 (28.8)	0.34
White blood cell count (/μl)	4,902 (1,489)	4,906 (1,319)	0.86
Hemoglobin (g/dl)	14.1 (1.3)	14.3 (1.4)	0.09
Platelets (10 <sup>9</sup> /L)	164 (56)	172 (55)	0.68
HCVRNA (10 <sup>3</sup> IU/ml)	1,859 (1,468)	2,021 (1,393)	0.09
ISDR mutations: ≥2 (%)	15 (%)	20 (%)	0.11
Core70: mutant (%)	36 (%)	29 (%)	0.22
Core91: mutant (%)	40 (%)	36 (%)	0.20
Fibrosis: F2–4 (%)	49 (%)	48 (%)	0.36
Activity: A2–3 (%)	42 (%)	34 (%)	0.10

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; LDL-C, low-density-lipoprotein-cholesterol; ISDR, interferon sensitivity-determining region. Data expressed as mean (SD).

0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity), and A3 (severe activity). Sustained virological response was defined as undetectable HCV RNA by qualitative PCR with a lower detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems) at week 24 after the completion of therapy.

### Statistical Analysis

A database of pretreatment variables included hematological tests (hemoglobin level, white blood cell count, and platelet count), blood chemistry tests (serum levels of creatinine, albumin, aspartate aminotransferase, alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C)), viral factors (HCV RNA titer, number of substitutions in ISDR, substitutions in the amino acid positions 70 and 91 of the core region), histological findings (stage of fibrosis and grade of activity) and patient characteristics (age, sex, and body mass index). Based on this database, decision-tree analysis was used to define a predictive model for sustained virological response.

Student's *t*-test was used for the univariable comparison of quantitative variables and Fisher's exact test was used for the comparison of qualitative variables. For the multivariable analysis for factors associated with sustained virological response, logistic regression models with backward selection were used to identify independent predictors of sustained virological response. Variables that showed significant association with sustained virological response by univariable analysis were included in the multivariable analysis. IBM-SPSS software v.15.0 (SPSS, Inc., Chicago, IL) was used for these analyses. For the decision-tree analysis [Segal and

Bloch, 1989], the data mining software IBM SPSS Modeler 13 (IBM SPSS, Inc.) was used, as reported previously [Kurosaki et al., 2010a,b]. In brief, the software searched for the optimal split variables to build a decision-tree structure. The entire study population was first evaluated to determine the variables and cut-off points for the most significant division into two subgroups having different probabilities of sustained virological response. Thereafter, analysis was repeated on all subgroups in the same way until either no additional significant variable was detected or the sample size was below 20.

## RESULTS

### Generation of the Decision-Tree Model

The decision-tree analysis selected five predictive variables to produce six subgroups of patients (Fig. 1). The number of substitutions in ISDR was selected as the best predictor of sustained virological response. The possibility of achieving sustained virological response was 83% for patients with two or more substitutions in ISDR compared with 44% for patients with a single or no substitution. Among patients with a single or no substitution in ISDR, age, with an optimal cut-off of 60 years, was selected as the variable of second split. Patients younger than 60 had the higher probability of sustained virological response (55%) compared with those older than 60 years (31%). Among younger patients, amino acid substitution at Core70 was selected as the third variable of split—wild-type sequence being the predictor of favorable response compared with the mutant type (65% vs. 36%). Among patients with wild-type Core70, the level of serum LDL-C was selected as the fourth variable of split, with an optimal cutoff of




Fig. 1. Decision-tree model. Boxes indicate the factors used for splitting and the cutoff value for the split. Pie charts indicate the rate of sustained virological response for each group of patients after splitting. Terminal subgroups of patients discriminated by the analysis are numbered from 1 to 7. The rate of sustained virological response was >80% in subgroups 1 and 2, 64% in subgroup 3, and 31–36% in subgroups 4, 5, and 6. LDL-C represents low-density lipoprotein cholesterol and Core70 represents amino acid substitution at position 70 of the core region.

120 mg/dl. Patients with higher LDL-C level had the higher probability of sustained virological response (83% vs. 50%). The stage of fibrosis was selected as the final variable of split, with significant fibrosis (F2–4) being the predictor of lower sustained virological response probability (64% vs. 32%).

Among the six subgroups derived by this decision tree, the subgroup of patients with two or more substitutions in ISDR (subgroup 1) or with a single or no substitution in ISDR but younger than 60 years of age, having the wild-type Core70 and high serum level of LDL-C ( $\geq 120$  mg/dl) (subgroup 2) showed the highest probability of sustained virological response (83%).

#### Validation of the Decision-Tree Model

The decision-tree model was validated using a validation dataset of 201 cases that were not included the model-building dataset. Each patient in the validation set was allocated to subgroups 1–6 using the flowchart form of the decision tree. The rates of sustained virological response were 75% for subgroup 1, 73% for subgroup 2, 65% for subgroup 3, 41% for subgroup 4, 46% for subgroup 5, and 33% for subgroup 6. The rates of sustained virological response for each subgroup of patients were correlated closely between the model building dataset and the validation dataset ( $r^2 = 0.94$ ) (Fig. 2).

*J. Med. Virol.* DOI 10.1002/jmv

The six subgroups were reconstructed into three groups according to their rate of sustained virological response: the high-probability group consisted of subgroups 1 and 2, the intermediate-probability group consisted of subgroup 3, and the low-probability group consisted of subgroups 4, 5, and 6. The rate of sustained virological response in the high-probability group was high on a consistent basis: 83% for model-building patients and 74% for validation patients. The rate of sustained virological response in the intermediate-probability group was 64% for model building patients and 65% for internal validation patients. The rate of sustained virological response in the low-probability group was low on a consistent basis: 32% for model-building patients and 36% for internal validation patients (Fig. 3). Thirty percent of the patients were classified into the high-probability group and 10% of the patients were classified into intermediate-probability group, which means that about 40% of patients with higher than average probability of achieving sustained virological response were identified.

#### Effect of Dose Reductions of PEG-IFN and RBV

The possible effect of drug reductions was analyzed in the three groups of patients divided by decision tree (low-, intermediate-, and high-probability groups)




Fig. 2. Validation of the decision-tree analysis: Subgroup-stratified comparison of the rate of sustained virological response. Each patient in the validation set was allocated to subgroups 1–6 by following the flowchart form of the decision tree, and the rates of sustained virological response were then calculated and plotted for each subgroup. The x-axis represents the rate of sustained virological response in the model-building datasets and the y-axis represents the rate of sustained virological response in the validation datasets. The rates of achieving sustained virological response in each subgroup of patients correlated closely between the model-building dataset and the validation dataset (correlation coefficient:  $r^2 = 0.94$ ).




Fig. 3. Comparison of sustained virological response rates between groups divided by the decision tree. The rate of sustained virological response was compared between three groups of patients as divided by the decision-tree analysis. Black, gray, and white boxes indicate the low-probability group (subgroup 4, 5, and 6), intermediate-probability group (subgroup 3), and high-probability group (subgroup 1 and 2), respectively. The rate of sustained virological response showed significant difference between the three groups.

(Fig. 4). Patients were stratified according to the cumulative drug exposure with PEG-IFN and RBV: the good adherence group consisted of patients who took  $\geq 80\%$  planned doses of both PEG-IFN and RBV; the poor adherence group consisted of patients who took  $< 80\%$  of planned doses of both PEG-IFN and RBV. Even after adjustment for drug adherence, the three groups of patients divided by decision-tree analysis still had low, intermediate, and high probability of achieving sustained virological response, respectively, indicating that this model predicts sustained virological response independent of drug exposure.

### Multivariable Logistic Regression Analysis

Age, sex, serum levels of creatinine, ALT, GGT, LDL-C, hemoglobin, platelet count, HCV RNA titer, ISDR substitution, substitution at Core70, substitution at Core91, histological stage of fibrosis, and grade of activity were found to be associated with sustained virological response by standard univariable analysis. Multivariable analysis including these factors showed that age, sex, LDL-C levels, GGT levels, platelet count, ISDR substitution, and substitution at Core70 showed independent associations with sustained virological response (Table II). Substitution in ISDR had the highest odds ratio, at 9.92. Fibrosis, which was selected as a significant predictor of response in the decision-tree analysis, was not found to be an independent predictor of response in standard multivariable analysis, indicating that the decision-tree analysis could identify significant predictors that would apply specifically to selected patients.

### DISCUSSION

The present study revealed that viral factors such as substitutions in ISDR and Core70 are significant and independent predictors of sustained virological response to PEG-IFN plus RBV in chronic hepatitis C. In a decision-tree model for the pretreatment prediction of sustained virological response, the number of substitutions in ISDR was the best predictor of sustained virological response, followed by younger age, wild-type sequence at Core70, higher level of LDL-C, and absent fibrosis. This decision-tree model could identify patients with high probability of sustained virological response (83%) among difficult-to-treat genotype 1b chronic hepatitis C patients. Using this model, rapid estimates of the response before treatment can be made by allocating patients to specific subgroups with a defined rate of response simply by following the flowchart form. Because more potent therapy, such as a combination of protease inhibitor, PEG-IFN, and RBV, is under clinical trial and may become available in the near future [Hezode et al., 2009; McHutchison et al., 2009], pretreatment prediction of the likelihood of sustained virological response may be useful for both patients and physicians to support clinical decisions whether to start current standard therapy or to wait for emerging new therapies.




Fig. 4. Comparison of the rate of sustained virological response between the decision-tree groups stratified by drug adherence. The three groups of patients divided by the decision tree (black, gray, and white boxes indicating the low-, intermediate-, and high-probability groups, respectively) were further stratified according to cumulative drug exposure to PEG-IFN and RBV.

Two or more substitutions in ISDR had a strong impact on sustained virological response, because this factor was selected as a top variable in decision-tree analysis and had the highest odds ratio in multivariable analysis. Moreover, even among patients with unfavorable ISDR (0 or 1 mutation), younger patients (<60 years) with the wild-type sequence at Core70 and high level of LDL-C ( $\geq 120$  mg/dl) had a high rate of sustained virological response. The sustained virological response rate of these two subgroups of patients was 83% in the model-building patients and 75% in the validation patients. Thus, patients with high possibility of sustained virological response could be extracted by the combined analysis of ISDR and Core70. These patients may be the best-suited candidates for treatment with the current combination therapy. Conversely, the following patients with 0–1 mutation in ISDR had a low probability of sustained virological response (32–35%): (1) older (>60 years); or (2) younger (<60 years) patients but having mutant-type sequence at Core70; or (3) younger (<60 years) patients having a wild-type sequence at Core70, but having a low level of LDL-C (<120 mg/dl) and advanced fibrosis. These patients may

be advised to wait for a more effective therapy. Decision may be made on a case-by-case basis, taking into account the potential risk of disease progression while waiting.

In a previous decision-tree model using simple and noninvasive standard tests that are available readily worldwide [Kurosaki et al., 2010b], the rate of sustained virological response was at most 65–76% among those in the high-probability group. That model focused on use by general physicians in routine general practice, especially where specialized resources, such as liver biopsy or determination of viral sequences, are not available. In that model, younger age, male sex, higher platelet counts, lower alpha-fetoprotein (AFP) levels, and lower GGT levels were identified as favorable predictive parameters. Higher AFP levels and lower platelet counts that are hallmarks of advanced fibrosis [Shiratori and Omata, 2000; Akuta et al., 2007b] were associated with low probability of sustained virological response in that model. On the other hand, the present analysis aimed to clarify the significance of viral factors for pretreatment prediction of sustained virological response, and to build an advanced model that may be used by specialist physicians engaged in the

TABLE II. Multivariable Logistic Regression Analysis for Factors Associated With SVR

Parameter		Odds	95% CI	P-value
Age (years)	<60 vs. $\geq 60$	2.28	1.31–3.94	0.003
Sex	Male vs. female	3.36	1.87–5.99	<0.0001
GGT (IU/L)	<40 vs. $\geq 40$	2.65	1.45–4.85	0.002
LDL-C (mg/dl)	$\geq 120$ vs. <120	1.79	0.91–3.53	0.094
Platelets (10 <sup>9</sup> /L)	$\geq 120$ vs. <120	2.69	1.22–5.90	0.014
ISDR mutations	$\geq 2$ vs. 0–1	9.92	3.71–26.54	<0.0001
Core70	Wild vs. mutant	1.92	1.07–3.47	0.030

GGT, gamma-glutamyltransferase; LDL-C, low-density-lipoprotein-cholesterol; ISDR, interferon sensitivity-determining region.



treatment of hepatitis. In the present model, stage of fibrosis was selected as a predictive factor, but at lower level of significance than HCV mutations. The predicted rate of sustained virological response in the high-probability group of the present model is higher than that in the previous model (75–83% vs. 65–76%). These results indicate that substitutions in ISDR and Core70 were important pretreatment predictors of sustained virological response. Determination of these viral factors is not available readily in clinical practice, but is of value for improving the accuracy of pretreatment prediction of sustained virological response.

Substitutions in ISDR and Core70 have been reported previously to be associated with efficacy of IFN therapy. The association between the number of substitutions in ISDR and response to therapy was demonstrated originally in patients treated with IFN mono-therapy [Enomoto et al., 1995, 1996; Kurosaki et al., 1997], but recent studies have reported a positive correlation with PEG-IFN and RBV combination therapy as well [Munoz de Rueda et al., 2008; Shirakawa et al., 2008; Ikeda et al., 2009]. Another important viral factor relevant to treatment response is amino acid substitution in Core70. The sequence of this amino acid was reported originally to be associated with nonresponse to therapy [Akuta et al., 2005], but subsequent studies confirmed the positive correlation of a wild-type Core70 with sustained virological response [Akuta et al., 2009]. The multiple logistic regression analysis showed that ISDR and Core70 were independent factors associated with sustained virological response along with host factors. How these important viral factors and other host factors can be combined to predict response to PEG-IFN plus RBV is an important clinical question. Decision-tree modeling can make the response probability apparent by combining all these factors. Some factors that may be associated with treatment outcome, such as levels of ferritin or homocysteine, were not included. This may be a potential limitation of the present study.

It is of interest that a recent study by Li et al. [2010] has shown that a high serum level of LDL-C is linked to the *IL28B* major allele (CC in rs12979860). In that study, a high serum level of LDL-C was associated with sustained virological response, but it was no longer significant when analyzed together with the *IL28B* genotype in multivariate analysis. Thus, the association between treatment response and LDL cholesterol levels in the present study may reflect the underlining link of LDL cholesterol levels to the *IL28B* genotype. Recent reports indicate that the *IL28B* genotype and HCV substitutions are correlated closely [Akuta et al., 2010; Kurosaki et al., 2010c]. Still, Core70 [Akuta et al., 2010] or ISDR [Kurosaki et al., 2010c] were predictors of response to therapy independent of *IL28B* genotype. Future study is needed to elucidate the possible mechanisms underlying the association between HCV sequences and host genetic factors, and also the role of host and viral factors for the prediction of treatment response.

In conclusion, a data mining analysis emphasized the impact of substitutions in ISDR and Core70 on pretreatment prediction of sustained virological response to PEG-IFN plus RBV therapy. A decision-tree model that includes substitutions in ISDR and Core70 of HCV could identify patients with high probability of sustained virological response, and could thereby improve the predictive accuracy over predictions that are based on standard tests.

## REFERENCES

- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 48:372–380.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. *J Hepatol* 46:403–410.
- Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. *J Med Virol* 79:1686–1695.
- Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2009. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response. *J Med Virol* 81:452–458.
- Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. *Hepatology* 52:421–429.
- Averbook BJ, Fu P, Rao JS, Mansour EG. 2002. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. *Surgery* 132:589–602.
- Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, Gornbein J, Geevarghese S, Nissen N, Farmer D, Demetriou A, Busuttill RW. 2003. Phosphorus and an early predictive factor in patients with acute liver failure. *Transplantation* 75:2007–2014.
- Bedossa P, Poinard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 24:289–293.
- Breiman L, Friedman RA, Olshen CJ, Stone CM. 1980. Classification and regression trees. CA: Wadsworth.
- Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 38:645–652.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest* 96:224–230.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 334:77–81.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.



- Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. 2005. Improved detection of prostate cancer using classification and regression tree analysis. *J Clin Oncol* 23:4322–4329.
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461:399–401.
- Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goesser T, Eronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 360:1839–1850.
- Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi M, Nagase Y, Takahashi H, Matsunaga K, Matsumoto N, Itoh F, Yotsuyanagi H, Koitabashi Y, Yasuda K, Iino S. 2009. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. *Hepatology* 49:753–759.
- Izumi N, Nishiguchi S, Hino K, Suzuki F, Kumada Y, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M. 2010. Management of hepatitis C; Report of the consensus meeting at the 45th annual meeting of the Japan society of hepatology (2009). *Hepatology* 40:347–368.
- Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. 2006. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology* 43:954–960.
- Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C, Ogura Y. 1997. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. *Hepatology* 25:750–753.
- Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higak M, Enomoto N, Izumi N. 2010a. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatology* 40:251–260.
- Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsushashi H, Izumi N. 2010b. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. *J Gastroenterol* DOI: 10.1007/s00535-010-0322-5.
- Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. 2010c. Pretreatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol* DOI: 10.1016/j.jhep.2010.07.037.
- LeBlanc M, Crowley J. 1995. A review of tree-based prognostic models. *Cancer Treat Res* 75:113–124.
- Lee SS, Ferenci P. 2008. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. *Antivir Ther* 13:9–16.
- Leiter U, Buettner PG, Eigentler TK, Garbe C. 2004. Prognostic factors of thin cutaneous melanoma: An analysis of the central malignant melanoma registry of the German Dermatological Society. *J Clin Oncol* 22:3660–3667.
- Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ. 2010. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. *Hepatology* 51:1904–1911.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. *Lancet* 358:958–965.
- McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 360:1827–1838.
- Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. 2002. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. *J Epidemiol* 12:243–248.
- Munoz de Rueda P, Casado J, Paton R, Quintero D, Palacios A, Gila A, Quiles R, Leon J, Ruiz-Extremera A, Salmeron J. 2008. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. *J Virol* 82:6644–6653.
- Segal MR, Bloch DA. 1989. A comparison of estimated proportional hazards models and regression trees. *Stat Med* 8:539–550.
- Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. *Hepatology* 48:1753–1760.
- Shiratori Y, Omata M. 2000. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: How does this modify the treatment course? *J Gastroenterol Hepatol* 15:E141–E151.
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 41:1100–1104.
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41:1105–1109.
- Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, Hatakeyama K. 2007. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. *Ann Surg Oncol* 14:34–40.
- Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL. 2008. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. *Hepatology* 47:1884–1893.
- Zlobec I, Steele R, Nigam N, Compton CC. 2005. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. *Clin Cancer Res* 11:5440–5443.

## Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis

Masayuki Kurosaki · Naoya Sakamoto · Manabu Iwasaki · Minoru Sakamoto · Yoshiyuki Suzuki · Naoki Hiramatsu · Fuminaka Sugauchi · Hiroshi Yatsuhashi · Namiki Izumi

Received: 22 June 2010 / Accepted: 21 August 2010  
© Springer 2010

### Abstract

**Background** This study aimed to develop a model for the pre-treatment prediction of sustained virological response (SVR) to peg-interferon plus ribavirin therapy in chronic hepatitis C.

**Methods** Data from 800 genotype 1b chronic hepatitis C patients with high viral load ( $>100,000$  IU/ml) treated by peg-interferon plus ribavirin at 6 hospitals in Japan were randomly assigned to a model building ( $n = 506$ ) or an internal validation ( $n = 294$ ). Data from 524 patients treated at 29 hospitals in Japan were used for an external validation. Factors predictive of SVR were explored using data mining analysis.

**Results** Age ( $<50$  years), alpha-fetoprotein (AFP) ( $<8$  ng/mL), platelet count ( $\geq 120 \times 10^9/l$ ), gamma-glutamyl-transferase (GGT) ( $<40$  IU/l), and male gender were used to build the decision tree model, which divided patients into 7 subgroups with variable rates of SVR ranging from 22 to 77%. The reproducibility of the model was confirmed by the internal and external validation ( $r^2 = 0.92$  and  $0.93$ , respectively). When reconstructed into 3 groups, the rate of SVR was 75% for the high probability group, 44% for the intermediate probability group and 23% for the low probability group. Poor adherence to drugs lowered the rate of SVR in the low probability group, but not in the high probability group.

M. Kurosaki · N. Izumi (✉)  
Division of Gastroenterology and Hepatology,  
Musashino Red Cross Hospital, 1-26-1 Kyonan-cho,  
Musashino, Tokyo 180-8610, Japan  
e-mail: nizumi@musashino.jrc.or.jp

M. Kurosaki  
e-mail: kurosaki@musashino.jrc.or.jp

N. Sakamoto  
Department of Gastroenterology and Hepatology,  
Tokyo Medical and Dental University, Tokyo, Japan  
e-mail: nsakamoto.gast@tmd.ac.jp

M. Iwasaki  
Department of Computer and Information Science,  
Seikei University, Tokyo, Japan  
e-mail: iwasaki@st.seikei.ac.jp

M. Sakamoto  
First Department of Internal Medicine, University of Yamanashi,  
Yamanashi, Japan  
e-mail: msakamoto@yamanashi.ac.jp

Y. Suzuki  
Department of Hepatology, Toranomon Hospital, Tokyo, Japan  
e-mail: suzunari@interlink.or.jp

N. Hiramatsu  
Department of Gastroenterology and Hepatology,  
Osaka University Graduate School of Medicine,  
Osaka, Japan  
e-mail: hiramatsu@gh.med.osaka-u.ac.jp

F. Sugauchi  
Department of Gastroenterology and Metabolism,  
Nagoya City University Graduate School of Medical Sciences,  
Nagoya, Japan  
e-mail: fsugauch@med.nagoya-cu.ac.jp

H. Yatsuhashi  
Clinical Research Center, National Nagasaki Medical Center,  
Nagasaki, Japan  
e-mail: yatsuhashi@nmc.hosp.go.jp

**Conclusions** A decision tree model that includes age, gender, AFP, platelet counts, and GGT is useful for predicting the probability of response to therapy with peg-interferon plus ribavirin and has the potential to support clinical decisions regarding the selection of patients for therapy.

**Keywords** Data mining · Decision tree · Alpha-fetoprotein · HCV · Peg-interferon

## Introduction

The current standard therapy for genotype 1 chronic hepatitis C is 48 weeks of pegylated interferon (PEG-IFN) plus ribavirin (RBV) [1]. Sustained virological response (SVR), defined as undetectable HCVRNA post-treatment is regarded as a cure of chronic hepatitis C. However, the rate of SVR to this regimen is only 50% in patients with HCV genotype 1b and a high HCVRNA titer [2, 3]. Since PEG-IFN and RBV combination therapy is costly and accompanied by potential adverse effects, the ability to predict the possibility of SVR before therapy may significantly influence the selection of patients for therapy. A recent report revealed that single nucleotide polymorphisms located in the *IL28B* are strongly associated with a response to PEG-IFN plus RBV therapy [4–6]. Besides, the amino acid substitutions in the NS5A [7–9] or core region of HCV were also associated with response to therapy [10, 11]. Unfortunately, these host genetic and viral factors are not yet readily available for general application in actual clinical practice. Fibrosis of the liver is also an important predictor of response, but resources may be limited in some countries. Clinical and non-invasive parameters may be better suited for general practice, but there is no established means by which the likelihood of a response can be predicted prior to therapy.

Data mining is a method of predictive analysis that explores data, without setting the hypothesis, to discover hidden patterns and relationships in highly complex datasets and enables the development of predictive models. Decision tree analysis is a core component of data mining and predictive modeling [12], and it is utilized by decision makers in various fields of business. Recent publications on decision tree analysis indicate its usefulness for defining prognostic factors in various diseases such as prostate cancer [13], diabetes [14], melanoma [15, 16], colorectal carcinoma [17, 18], and liver failure [19]. The results of the analysis are presented as a tree structure, which is intuitive and facilitates the allocation of patients into subgroups by following the flow chart form [20]. We have recently reported the usefulness of decision tree analysis for the prediction of early virological response (undetectable

HCVRNA within 12 weeks of therapy) to PEG-IFN and RBV combination therapy in chronic hepatitis C [21].

In the present study, we used decision tree analysis to explore baseline predictors of response to PEG-IFN/RBV therapy so that a pre-treatment algorithm could be created to discriminate chronic hepatitis C patients who are likely to respond to PEG-IFN/RBV therapy from those who are not. For the purpose of use in general practice, only clinical and non-invasive parameters were included in the analysis.

## Materials and methods

### Patients

This was a multicenter retrospective cohort study supported by the Japanese Ministry of Health, Labor and Welfare. Data were collected from a total of 800 chronic hepatitis C patients who received therapy for 48 weeks with PEG-IFN alpha-2b and RBV at Musashino Red Cross Hospital, Toranomon Hospital, Tokyo Medical and Dental University, Osaka University, Nagoya City University Graduate School of Medical Sciences, Yamanashi University, and their related hospitals. The inclusion criteria to be enrolled in this study were as follows (1) infection by genotype 1b, (2) HCVRNA higher than 100,000 IU/ml by quantitative PCR (Cobas Amplicor HCV Monitor v 2.0, Roche Diagnostic systems, CA), which is typically used for the definition of high viral load in Japan, (3) lack of co-infection with hepatitis B virus or human immunodeficiency virus, (4) lack of other causes of liver disease such as autoimmune hepatitis and primary biliary cirrhosis and (5) completion of at least 12 weeks of therapy. Patients received PEG-IFN alpha-2b (1.5 µg/kg) subcutaneously every week and were administered a weight-adjusted dose of RBV (600 mg for <60 kg, 800 mg for 60–80 kg, and 1,000 mg for >80 kg), which is the recommended dosage in Japan. Patients who were treated for more than 49 weeks were not included in the study. For the analysis, patients were randomly assigned to either the model building ( $n = 506$ ) or the internal validation ( $n = 295$ ) group. Consent was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review committee. The baseline characteristics and representative laboratory test results are listed in Table 1. The overall rate of SVR was 47% in the model building set and 49% in the validation set. There were no significant differences in the clinical backgrounds between these 2 groups.

For external validation of the model, we collaborated with another study group supported by the Japanese Ministry of Health, Labor and Welfare. This multicenter study group consisted of 29 medical centers and hospitals

**Table 1** Comparison of pre-treatment factors between model building and internal validation patients

	Model (n = 506)	Validation (n = 295)
Age (years)	56 (14–75)	55 (18–74)
Male gender <sup>a</sup>	261/506 (52%)	160/295 (54%)
Body mass index (kg/m <sup>2</sup> )	22.9 (14.3–34.0)	23.2 (16.1–33.8)
Albumin (g/dl)	4 (2.7–5.0)	4 (2.8–4.9)
Creatinine (mg/dl)	0.7 (0.4–1.5)	0.7 (0.4–1.1)
AST (IU/l)	60 (11–370)	62 (11–240)
ALT (IU/l)	73 (11–413)	73 (14–390)
GGT (IU/l)	56 (10–328)	55 (7–409)
Total cholesterol (mg/dl)	173 (73–297)	171 (29–273)
Triglyceride (mg/dl)	105 (33–474)	109 (32–372)
White blood cell count (/μl)	4,745 (1,800–10,900)	4,823 (1,200–9,700)
Neutrophil count (/μl)	2,563 (667–7,870)	2,484 (508–7,579)
Red blood cell count (/μl)	448 (313–577)	451 (313–574)
Hemoglobin (g/dl)	14.1 (9.4–18.3)	14.1 (10.0–18.0)
Hematocrit (%)	41.7 (13.3–53.7)	41.9 (15.5–52.7)
Platelets (10 <sup>9</sup> /l)	164 (52–380)	158 (43–312)
AFP (ng/ml)	14.7 (0.9–680)	13 (0.8–323)
HCV RNA (10 <sup>3</sup> IU/ml)	1,852 (100–5,100)	1,870 (100–5,100)
Fibrosis stage: F3–4	73/417 (18%)	48/247 (19%)

Data expressed as median (range) unless otherwise indicated

AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyltransferase, AFP alpha-fetoprotein

<sup>a</sup> Data expressed as number/available data (percentage)

belonging to the National Hospital Organization. A dataset collected from 524 patients who were treated with PEG-IFN alpha-2b/RBV was used as an external validation dataset, i.e., completely independent from the dataset that was used for model building.

#### Laboratory tests

Blood samples were obtained before therapy and at least once every month during therapy, and were used for hematologic tests, blood chemistry analysis and determination of HCV RNA. Pretreatment levels of HCV RNA were quantified by Cobas Amplicor (Roche Diagnostic Systems, Pleasanton, CA). SVR was defined as undetectable HCV RNA at week 24 after completion of therapy, as determined by qualitative PCR with a lower end detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems). Liver biopsy was available in 664 patients. Fibrosis and activity

were scored according to the METAVIR scoring system [22]. Fibrosis was staged on a scale of 0–4: F0 (no fibrosis), F1 (mild fibrosis: portal fibrosis without septa), F2 (moderate fibrosis: few septa), F3 (severe fibrosis: numerous septa without cirrhosis) and F4 (cirrhosis). Activity of necroinflammation was graded on a scale of 0–3: A0 (no activity), A1 (mild activity), A2 (moderate activity) and A3 (severe activity).

#### Statistical analysis

A database of pretreatment variables was created containing 6 variables from hematological tests (red blood cells, hemoglobin, hematocrit, white blood cells, neutrocytes and platelets), 8 variables from the blood chemistry test [creatinine, albumin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase (GGT), total cholesterol, triglyceride and alpha-fetoprotein (AFP)], serum level of HCV RNA and 3 variables for patient characteristics (age, gender and body mass index). Based on this database, the recursive partitioning analysis algorithm referred to as decision tree analysis was implemented to define meaningful subgroups of patients with respect to the possibility of achieving SVR.

Decision tree analysis is a family of nonparametric regression methods. Software is used to automatically explore the data to search for optimal split variables and to build a decision tree structure [23]. For the analysis, the entire study population was evaluated to determine which variables and cutoff points yielded the most significant division into 2 prognostic subgroups that were as homogeneous as possible for the probability of SVR. Thereafter, the same analytic process was applied to all newly defined subgroups. A restriction was imposed on the tree construction such that the procedure stopped when either no additional significant variable was detected or when the sample size was below 20. For this analysis, the data mining software IBM SPSS Modeler 13 (IBM SPSS Inc., Chicago, IL) was utilized. SPSS software v.15.0 (SPSS Inc., Chicago, IL) was used for multivariate logistic regression analysis.

## Results

### Decision tree analysis

Decision tree analysis was carried out on the model building dataset from 506 patients using 18 variables. Figure 1 shows the results. The analysis automatically selected 5 predictive variables to produce a total of 7 subgroups of patients. Age was selected as the variable of initial split with an optimal cutoff of 50 years. The possibility of achieving SVR was 41% for patients older than 50 compared to 70% for patients